Scientific Program

Preliminary program subject to change

Monday, 3 December 2018

08:00-17:00

Registration 

Session 1: Publication and presentation of studies

Editorial decision making: fair or fanciful?

Reviewing clinical trials: does the standard need upgrading?

How to write an unattractive clinical trials abstract

Coffee Break and visit the Exhibition

Session 2: Observational and real-life studies: insecure?

Are most pharmacoepidemiological studies data junk?  Can confounding be overcome?

Meta-analysis: mostly a confidence trick?

CVD-REAL: real-value or misleading?

Lunch Break and visit the Exhibition

Session 3: Statistical issues for RCTs

Prospensity matching: uses and limitations

Hierachical testing: uses and limitations

Multivariable analysis: approaches and interpretation

Coffee Break and visit the Exhibition

Session 4: Safety and tolerability data – insensitive and overwhelming?


Uncommon things commonly occur:  how best to handle 1000's of SAEs


Which PROM? satisfaction, quality of life, and many others

                             

Poster session with presenters and moderators

 

Tuesday, 4 December 2018

08:00-17:00

Registration 

Session 5: Use of CGM in glucose-outcome studies; ensuring validity

What is needed to make it acceptable to regulators?

How to define a hypoglycaemic episode from continuous data

CGM: the problem of hyper-repeated measurement and valid statistical

analysis

Panel discussion

Coffee Break and visit the Exhibition

Session 6: RCTs in the medication development programme

What would be the manufacturer wish list?

Are the regulatory authorities looking for changes?

Have CVOTs gone off the rails – should the paradigm change?

Panel discussion

Lunch Break and visit the Exhibition

Session 7: Data issues – from big to long


Can we successfully use data from large populations and diverse datasets

(big data)?

Can site-less and pragmatic studies be trusted?

Understanding legacy effects: epidemiology or metabolic memory?

Coffee Break and visit the Exhibition

Session 9: Outcomes: class or individual medication effects?

SGT-2 blockers

DPP-4 inhibitors

GLP-1RAs

Panel discussion

Congress closing